{
    "clinical_study": {
        "@rank": "147865", 
        "acronym": "NPC", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo qd (2# bid) for 3 years"
            }, 
            {
                "arm_group_label": "Epigallocatechin Gallate (EGCG)", 
                "arm_group_type": "Experimental", 
                "description": "EGCG 600 mg qd (2# bid) for 3 years"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the EBV reactivation rate in post-radiation and\n      remission NPC patients, evaluate the safety and tolerance of EGCG and analyze the\n      observational correlation between EBV reactivation and clinical outcome."
        }, 
        "brief_title": "Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "NPC", 
        "detailed_description": {
            "textblock": "Patients with pathologically proven NPC, stage II-IVB and finishing curative RT \u226770 Gy\n      within 6 months (\u00b1 induction/concurrent/adjuvant chemotherapy) will be candidates for this\n      study. Before entry, 8 CC venous blood will be obtained for EBV DNA and antibody screen\n      tests after patient's consent. Those who have undetectable plasma EBV DNA (0 copy/ml) and\n      fulfilled with all inclusion and exclusion criteria will be registered.\n\n      Routine re-staging work-ups after RT should show no active lesion in nasopharynx, neck and\n      distant organs. Re-staging survey should include nasopharyngoscope, pEBV DNA assay, CBC,\n      platelet count, renal and liver function tests, CXR, abdominal sonography or CT scan, whole\n      body bone scan, MRI or CT scan of the head and neck region.\n\n      Within one week after finishing registration, EGCG or placebo should be started.  A blood\n      sample before taking EGCG/placebo will be collected for antibodies test and pEBV DNA assay."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven NPC.\n\n          -  2010 AJCC stage II-IVB.\n\n          -  Age \u2267 20 years old.\n\n          -  Performance status of ECOG \u2266 2.\n\n          -  Finished RT \u226770 Gy within 6 months (\u00b1 induction/concurrent/adjuvant chemotherapy).\n\n          -  Clinical complete remission by re-staging work-ups within 3 months before entry.\n\n          -  Plasma EBV DNA = 0 copy/ml within 4 weeks before entry.\n\n          -  Adequate liver, renal, and bone marrow function:Serum total bilirubin level \u2266 2.5\n             mg/dl. Serum creatinine \u2266 1.6 mg/dl. WBC \u2267 3,000/ul. Platelet count \u2267 100,000/ul.\n\n          -  No intake of EGCG or similar dietary supplements.\n\n          -  Signed informed consent.\n\n          -  No further anti-cancer treatment.\n\n        Exclusion Criteria:\n\n          -  Occurrence of locoregional recurrence or distant metastasis.\n\n          -  Inadequate RT or finishing RT > 6 months.\n\n          -  Not complete remission by re-staging work-ups within 3 months before entry.\n\n          -  Plasma EBV DNA > 0 copy/ml within 4 weeks before entry.\n\n          -  Intake of EGCG or similar dietary supplements during recent 3 months.\n\n          -  Severe cardiopulmonary diseases (unstable angina and/or congestive heart failure or\n             peripheral vascular disease requiring hospitalization within the last 12 months;\n             chronic obstructive pulmonary disease exacerbation other respiratory illness\n             requiring hospitalization) or clinically significant psychiatric disorders."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "352", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01744587", 
            "org_study_id": "T2312"
        }, 
        "intervention": [
            {
                "arm_group_label": "Epigallocatechin Gallate (EGCG)", 
                "description": "EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.", 
                "intervention_name": "Epigallocatechin Gallate (EGCG)", 
                "intervention_type": "Other", 
                "other_name": "EGCHAC-purified EGCG 90% capsules"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Placebo qd (2# bid) for 3 years", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "Placebo"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Epigallocatechin gallate"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "EBV", 
            "EGCG"
        ], 
        "lastchanged_date": "October 28, 2013", 
        "location": {
            "contact": {
                "email": "jclin@vghtc.gov.tw", 
                "last_name": "Jin Ch Lin, MD PHD", 
                "phone": "+8864-23592525", 
                "phone_ext": "5613"
            }, 
            "contact_backup": {
                "email": "walter@nhri.org.tw", 
                "last_name": "Tsang Wu Liu, MD", 
                "phone": "+886-37-246166", 
                "phone_ext": "35120"
            }, 
            "facility": {
                "address": {
                    "city": "Zhunan", 
                    "country": "Taiwan", 
                    "state": "Miaoli", 
                    "zip": "350"
                }, 
                "name": "Taiwan Cooperative Oncology Group, National Health Research Institutes"
            }, 
            "investigator": [
                {
                    "last_name": "Jin Ch Lin, MD PHD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Yi Fa Chang, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Wen Ch Chen, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jenn Re Hsiao, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Taiwan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of Epstein-Barr Virus Reactivation and the Effect of Dietary Supplement Epigallocatechin Gallate (EGCG) on Virus Reactivation in Remission Patients With Nasopharyngeal Carcinoma - A Randomized Trial", 
        "overall_contact": {
            "email": "jclin@vghtc.gov.tw", 
            "last_name": "Jin Ch Lin, MD PHD", 
            "phone": "+856-4-23592525", 
            "phone_ext": "5613"
        }, 
        "overall_contact_backup": {
            "email": "yhchin@nhri.org.tw", 
            "last_name": "Yung Hs Chin, MSN", 
            "phone": "+886-37-246-166", 
            "phone_ext": "35119"
        }, 
        "overall_official": [
            {
                "affiliation": "Taiwan Cooperative Oncology Group, National Health Research Institutes", 
                "last_name": "Tsang Wu Liu, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Taichung Veterans General Hospital", 
                "last_name": "Jin Ch Lin, MD PHD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "National Institute of Cancer Research, National Health Research Institutes", 
                "last_name": "Jen Ya Chen, PHD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Taiwan: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Reactivation of EBV is defined as\n1.Antibody against EBV VCA: The IgA antibody titers will be detected by a commercial EBV VCA ELISA kit (RE 562 71, Immuno-Biological Laboratories, Germany) Patient's serum with anti-EBV VCA greater than 10U/ml will be considered as reactivation of EBV.", 
            "measure": "EBV reactivation rates between EGCG and placebo group", 
            "safety_issue": "Yes", 
            "time_frame": "every 3 months for the first 3 years and every 6 months thereafter for antibodies tests and pEBV DNA assay (total 5 years)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01744587"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Observational analysis of the correlation between EBV reactivation and clinical outcome", 
            "measure": "Correlation between EBV reactivation and OS/RFS", 
            "safety_issue": "Yes", 
            "time_frame": "q 3 months for first 3 years and q 6 months for the"
        }, 
        "source": "National Health Research Institutes, Taiwan", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Mackay Memorial Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Taichung Veterans General Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Cheng-Kung University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Chang Gung Memorial Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "China Medical University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "National Taiwan University Hospital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Health Research Institutes, Taiwan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}